

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: BioMark Diagnostics Inc. (the "Issuer").

Trading Symbol: BUX

Number of Outstanding Listed Securities: 65,015,119

Date: December 4th, 2018

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer continued its business developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor, and assess treatment for cancer early, accurately and cost effectively.

2. Provide a general overview and discussion of the activities of management.
- **Management continues to raise capital through private placement, family funds and other strategic sources to support completion of clinical trials studies, regulatory submission and commercialization of its technology platform. Management has been working on numerous non-dilutive financing with various government institutions and strategic investors across Canada and United States.**
 - **On November 5, 2018, BioMark was pleased to announce that it appointed Dr. Myron Weisfeldt to its scientific advisory team. Dr. Weisfeldt is a member of the National Academy of Medicine, also is professor of Medicine and the Senior Medical Director of Johns Hopkins Technology Ventures. In this position he provides advice on strategies and evaluation of intellectual property of Johns Hopkins faculty. Dr. Weisfeldt provided BioMark with excellent counsel on how to fine tune its lung cancer clinical trial protocol, FDA positioning and opened potential new opportunities for collaboration. That is what BioMark needs as the company transitions into a fully commercial entity.**
 - **On November 7, 2018, BioMark obtained the third batch of samples from Cooperative Human Tissue Network (CHTN) that will be used in confirmation of its lung cancer metabolite panel. The goal is to obtain over 800 samples across N. America so that a lab developed test can be prototyped for clinical application. CHTN is a unique National Cancer Institute (NCI) supported resource with distributed national centres. In addition, BioMark has commenced discussions with a certified lab service provider that will provide beta testing services for the test kits if both parties accept the terms of arrangement.**
 - **On November 13, 2018, Drs Maksymiuk AW, Sitar DS and Tappia PS. presented “Competition to Enhance Screening for Lung Cancer - Potential Role for SSAT Testing and Targeted Metabolomics” at CancerCare Manitoba, Haematology/Oncology Grand Rounds, Winnipeg, Canada.**
 - **On November 22, 2018, the manuscript entitled “Use of Amantadine as Substrate for SSAT-1 Activity as a Reliable Clinical Diagnostic Assay for Breast and Lung Cancer” was accepted for publication in Future Science OA. Additional papers are planned to be submitted for publication in December of 2018.**
 - **On November 23, 2018, Interim Financial Statement and MD&A were filed in SEDAR and Canadian Securities Exchange as required by regulators.**

- On November 26, 2018, BioMark Diagnostics Inc. held its Annual General Meeting at 17th Floor - 1030 West Georgia St., Vancouver, BC V6E 2Y3 on Monday, at 9:00 a.m. (Vancouver Time).
- On November 28, 2018, BioMark team was invited by Dean Reece to attend “SOM Festival of Science 2018” at School of Medicine, University of Maryland. During the visit held from November 27 to December 2, BioMark team presented the utility of its metabolomics powered technology platform to principle investigators for both lung and brain cancers. BioMark’s assays can be used in measuring tumour activity and potentially monitor response to treatment. Additionally, BioMark team visited the latest biobank and discussed the potential of obtaining samples that could support both retrospective and longitudinal studies for both lung and brain cancers. BioMark signed two CDAs and discussed avenues for establishing MOU between BioMark and the institutions in Maryland. This activity was supported by Going Global Innovation Program offered by Global Affairs Canada with key objectives of developing and validating BioMark’s robust markers with international partners.

About Going Global Innovation Program

The Going Global Innovation (GGI) program is specifically designed to promote and enhance Canada’s international innovation efforts. The program supports researchers who aim to commercialize technology by pursuing collaborative international research and development (R&D) opportunities through partnerships with key players in foreign markets.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not applicable.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Not applicable.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable.

8. Describe the acquisition of new customers or loss of customers.

Not applicable.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

The Issuer continues to file trademark and patents in specific jurisdictions for all its patents. Review of the filings and opinions from patent offices are being reviewed as needed.

10. Report on any employee hiring, terminations or lay-offs with details of anticipated length of lay-offs.

Not applicable.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not applicable.

14. Provide details of any securities issued and options or warrants granted.

Not applicable.

15. Provide details of any loans to or by Related Persons.

Not applicable.

16. Provide details of any changes in directors, officers, or committee members.

Not applicable

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are discussed in the Form 51-102F1 Management's Discussion & Analysis Annual Report for the Year Ended March 31, 2018.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there where is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated December 4th, 2018.

Rashid Ahmed BUX
Name of Director or Senior
Officer

"Rashid Ahmed Bux"
Signature

President & CEO
Official Capacity

| | | |
|-------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|------------------------------------------|
| Issuer Details Name of Issuer BioMark Diagnostics Inc. | For Month End November, 2018 | Date of Report YY/MM/DD 2018/12/04 |
| Issuer Address 165-10551 Shellbridge Way | | |
| City/Province/Postal Code Richmond, BC, V6X 2W8 | Issuer Fax No. N/A | Issuer Telephone No. (604) 370-0779 |
| Contact Name Rashid Ahmed Bux | Contact Position CEO | Contact Telephone No. (604) 370-0779 |
| Contact Email Address info@biomarkdiagnostics.com | Web Site Address www.biomarkdiagnostics.com | |